ASCT2 is upregulated in several cancers, such as prostate cancer, lung cancer, rectal adenocarcinoma, pancreatic cancer, melanoma, and oral squamous cell carcinoma (OSCC), and has emerged as a potential cancer therapeutic target [61, 62, 63, 64, 65]. Here, SLC1A5 is linked to cancer.